The Biotechnology Innovation Organization is concerned that Medicare’s restrictive coverage decision for new anti-amyloid Alzheimer’s drugs is indicative of a broader Centers for Medicare and Medicaid Services' mindset that accelerated approvals are “lesser” and that such a belief may “bleed over” to the private sector or other CMS payment strategies.
In an interview with Pink Sheet at BIO’s annual convention in Boston, Chief Advocacy Officer Nick Shipley made clear the...






